

Special Issue

Comprehensive Review on Upper Tract Urothelial Carcinoma: An Update in 2023

Message from the Guest Editors

Upper tract urothelial carcinoma (UTUC) is a relatively uncommon type of cancer, yet its incidence has risen in the past few decades mainly due to improved detection through advanced imaging and endoscopic technologies. It is an aggressive tumor with up to 60% and 25% of patients presenting with non-organ confined and metastatic diseases at diagnosis, respectively. Moreover, despite surgery with curative intent, long-term cancer-specific survival is still low, predominantly due to undetected microscopic metastasis. The management and prognosis of UTUC have improved in recent years given the widespread use of minimally invasive approaches and novel neoadjuvant and adjuvant systemic therapies. This Special Issue aims to highlight different aspects of multidisciplinary management of UTUC, including imaging, novel diagnostic markers, neoadjuvant and adjuvant therapies, and surgical interventions.

Guest Editors

Dr. Hooman Djaladat

Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

Dr. Alireza Ghoreifi

Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149614

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)